Real-world data continue to quantify treatment tradeoffs in atrial fibrillation. A population-level analysis reported that over 38% of very elderly atrial fibrillation patients (age 80+) were not on oral anticoagulants at discharge. Another study examining stroke survivors in a registry linked stopping prescribed oral anticoagulants to worse long-term self-assessed health status over three years in atrial fibrillation patients, reinforcing the downstream consequences of medication discontinuation beyond short-term events.